UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 193

Sortiert nach

Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer

Annals of oncology, 2018-12, Vol.29 (12), p.2334-2340

2018

Volltextzugriff (PDF)

Endocrine therapy or chemotherapy as first-line therapy in hormone receptor–positive HER2-negative metastatic breast cancer patients

European journal of cancer (1990), 2018-05, Vol.95, p.93-101

2018

Volltextzugriff (PDF)

5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study

European journal of cancer (1990), 2018-05, Vol.95, p.30-37

2018

Volltextzugriff (PDF)

Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial

European urology, 2018-05, Vol.73 (5), p.696-703

2018

Volltextzugriff (PDF)

Corrigendum to “De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): characteristics and prognosis” [Eur J Cancer 158 (2021) 181–188]

European journal of cancer (1990), 2022-05, Vol.166, p.311-312

2022

Volltextzugriff (PDF)

De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): Characteristics and prognosis

European journal of cancer (1990), 2021-11, Vol.158, p.181-188

2021

Volltextzugriff (PDF)

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas

British journal of cancer, 2017-09, Vol.117 (7), p.947-953

2017

Volltextzugriff (PDF)

Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity

Annals of oncology, 2007-08, Vol.18 (8), p.1335-1341

2007

Volltextzugriff (PDF)

Abstract OT1-04-07: VICTORIANE: A randomized phase 3 study assessing the addition of oral vinorelbine to aromatase inhibitors for the treatment of patients with metastatic breast cancer

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.OT1-04-07-OT1-04-07

2017

Volltextzugriff (PDF)

Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study

Annals of oncology, 2023-08, Vol.34 (8), p.670-680

2023

Volltextzugriff (PDF)

Abstract P4-21-41: Primary analysis of BERENICE: A phase II cardiac safety study of pertuzumab, trastuzumab, and neoadjuvant anthracycline-based chemotherapy in patients with locally advanced, inflammatory, or early-stage, unilateral, and invasive HER2-positive breast cancer

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P4-P4-21-41

2017

Volltextzugriff (PDF)

Long-term results of adjuvant hypofractionated radiotherapy for breast cancer in elderly patients

International journal of radiation oncology, biology, physics, 2005, Vol.61 (1), p.154-162

2005

Volltextzugriff (PDF)

Health‐Related Quality of Life With Adjuvant Docetaxel‐ and Trastuzumab‐Based Regimens in Patients with Node‐Positive and High‐Risk Node‐Negative, HER2‐Positive Early Breast Cancer: Results from the BCIRG 006 Study

The oncologist (Dayton, Ohio), 2013, Vol.18 (7), p.812-818

2013

Volltextzugriff (PDF)

OT1-03-02: SAFIR01: A Molecular Screening Trial for Metastatic Breast Cancer Patients

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.OT1-03-02-OT1-03-02

2011

Volltextzugriff (PDF)

Effect of acute global ischemia on the upper limit of vulnerability: a simulation study

American journal of physiology. Heart and circulatory physiology, 2004-06, Vol.286 (6), p.H2078-H2088

2004

Volltextzugriff (PDF)

Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation

British journal of cancer, 2004-08, Vol.91 (4), p.613-617

2004

Volltextzugriff (PDF)

P3-17-06: Final Results of a Controlled, Randomized 3-Arm Phase II Trial of EndoTAG”-1, a Cationic Liposomal Formulation of Paclitaxel Targeting Tumor Endothelial Cells, in Advanced Triple-Negative Breast Cancer (TNBC)

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.P3-P3-17-06

2011

Volltextzugriff (PDF)

Simulation of action potentials from metabolically impaired cardiac myocytes : Role of ATP-sensitive K+ current

Circulation research, 1996-08, Vol.79 (2), p.208-221

1996

Volltextzugriff (PDF)

Single-Agent Gemcitabine Is Active in Previously Treated Metastatic Breast Cancer

Oncology, 2001-01, Vol.60 (4), p.303-307

2001

Volltextzugriff (PDF)

Mechanistic investigation of extracellular K+ accumulation during acute myocardial ischemia: a simulation study

American journal of physiology. Heart and circulatory physiology, 2002-08, Vol.283 (2), p.H490-H500

2002

Volltextzugriff (PDF)

Abstract S1-4: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of AMG 479 With Exemestane (E) or Fulvestrant (F) in Postmenopausal Women With Hormone-Receptor Positive (HR+) Metastatic (M) or Locally Advanced (LA) Breast Cancer (BC)

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24_Supplement), p.S1-S1-4

2010

Volltextzugriff (PDF)

Effects of pinacidil on reentrant arrhythmias generated during acute regional ischemia: a simulation study

Annals of biomedical engineering, 2005-07, Vol.33 (7), p.897-906

2005

Volltextzugriff (PDF)

What do you think about generic drugs products? Results from a survey

Clinical therapeutics, 2015-08, Vol.37 (8), p.e130-e131

2015

Volltextzugriff (PDF)

Epidermal growth factor receptor expression in 780 breast cancer patients: A reappraisal of the prognostic value based on an eight-year median follow-up

Annals of oncology, 2001-06, Vol.12 (6), p.841-846

2001

Volltextzugriff (PDF)

1 – 25 von 193

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(141)
Mit Volltextzugriff
(179)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(165)
Life Sciences & Biomedicine
(108)
Humans
(63)
Technology
(58)
Engineering
(44)
Biological And Medical Sciences
(40)
Engineering, Biomedical
(37)
Physical Sciences
(37)
Female
(36)
Medical Sciences
(34)
Computer Simulation
(32)
Cardiac & Cardiovascular Systems
(31)
Cardiovascular System & Cardiology
(31)
Computer Science
(31)
Physics
(31)
Computer Science, Interdisciplinary Applications
(28)
Oncology
(28)
Adult
(26)
Middle Aged
(26)
Aged
(24)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer

Endocrine therapy or chemotherapy as first-line therapy in hormone receptor–positive HER2-negative metastatic breast cancer patients

5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study

Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial

Corrigendum to “De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): characteristics and prognosis” [Eur J Cancer 158 (2021) 181–188]

De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): Characteristics and prognosis

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas

Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity

Abstract OT1-04-07: VICTORIANE: A randomized phase 3 study assessing the addition of oral vinorelbine to aromatase inhibitors for the treatment of patients with metastatic breast cancer

Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study

Abstract P4-21-41: Primary analysis of BERENICE: A phase II cardiac safety study of pertuzumab, trastuzumab, and neoadjuvant anthracycline-based chemotherapy in patients with locally advanced, inflammatory, or early-stage, unilateral, and invasive HER2-positive breast cancer

Long-term results of adjuvant hypofractionated radiotherapy for breast cancer in elderly patients

Health‐Related Quality of Life With Adjuvant Docetaxel‐ and Trastuzumab‐Based Regimens in Patients with Node‐Positive and High‐Risk Node‐Negative, HER2‐Positive Early Breast Cancer: Results from the BCIRG 006 Study

OT1-03-02: SAFIR01: A Molecular Screening Trial for Metastatic Breast Cancer Patients

Effect of acute global ischemia on the upper limit of vulnerability: a simulation study

Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation

P3-17-06: Final Results of a Controlled, Randomized 3-Arm Phase II Trial of EndoTAG”-1, a Cationic Liposomal Formulation of Paclitaxel Targeting Tumor Endothelial Cells, in Advanced Triple-Negative Breast Cancer (TNBC)

Simulation of action potentials from metabolically impaired cardiac myocytes : Role of ATP-sensitive K+ current

Single-Agent Gemcitabine Is Active in Previously Treated Metastatic Breast Cancer

Mechanistic investigation of extracellular K+ accumulation during acute myocardial ischemia: a simulation study

Abstract S1-4: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of AMG 479 With Exemestane (E) or Fulvestrant (F) in Postmenopausal Women With Hormone-Receptor Positive (HR+) Metastatic (M) or Locally Advanced (LA) Breast Cancer (BC)

Effects of pinacidil on reentrant arrhythmias generated during acute regional ischemia: a simulation study

What do you think about generic drugs products? Results from a survey

Subcutaneous Interleukin-2 and Interferon Alfa Administration in Patients With Metastatic Renal Cell Carcinoma: Final Results of SCAPP III, a Large, Multicenter, Phase II, Nonrandomized Study With Sequential Analysis Design—The Subcutaneous Administration Propeukin Program Cooperative Group

Epidermal growth factor receptor expression in 780 breast cancer patients: A reappraisal of the prognostic value based on an eight-year median follow-up

Suchergebnisse filtern